Centers & Labs

RIKEN Center for Integrative Medical Sciences

Laboratory for Immune Regulation

Group Director: Masaru Taniguchi (M.D., Ph.D)
Masaru  Taniguchi(M.D., Ph.D)

The immune system is composed of the innate and acquired systems. In order to achieve effective immune responses, NKT cell-mediated adjuvant activity is essential to help proliferation, expansion of immune cells and activation of their functions, mediating protection against pathogen infection and cancer, as well as maintenance of transplantation tolerance and also suppression of autoimmune disease development. We focus on the mechanisms of NKT cell function and development. We are also conducting the development of NKT cell-targeted anti-tumor immunotherapy on solid tumor patients as the AMED project.

Main Research Field

Medicine, dentistry, and pharmacy

Related Research Fields

Biological Sciences / Biology

Keywords

  • Immune cells
  • Novel Immuno therapy
  • Autoimmune diseases
  • Cancer
  • Allergy

Selected Publications

  1. Seino K, Harada M, Taniguchi M.:
    "NKT cells are relatively resistant to apoptosis."
    Trends Immunol., 25, 219-221(2004).
  2. Watarai H, Nakagawa R, Omori-Miyake M, Nyambayar D, Taniguchi M.:
    "Methods for detection, isolation, and culture of mouse and human invariant NKT cells."
    Nat Protocols., 3, 70-78(2008).
  3. Terashima A, Watarai H, Inoue S, Sekine E, Nakagawa R, Hase K, Iwamura C, Nakajima H, Nakayama T, Taniguchi M.:
    "A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity."
    The Journal of Experimental Medicine, 205, 2727-2733(2008).
  4. Watarai H, Rybouchkin A, Hongo N, Nagata Y, Sakata S, Sekine E, Dashtsoodol N, Tashiro T, Fujii SI, Shimizu K, Mori K, Masuda K, Kawamoto H, Koseki H, Taniguchi M.:
    "Generation of functional NKT cells in vitro from embryonic stem cells bearing rearranged invariant Va14-Ja18 TCRa gene."
    Blood, 115, 230-237 (2010).
  5. Fujii S, Motohashi S, Shimizu K, Nakayama T, Yoshiga Y, Taniguchi M.:
    "Adjuvant activity mediated by iNKT cells."
    Semin Immunol., 22, 97-102(2010).
  6. Watarai H, Fujii SI, Yamada D, Rybouchkin A, Sakata S, Nagata Y, Iida-Kobayashi M, Sekine-Kondo E, Shimizu K, Shozaki Y, Sharif J, Matsuda M, Mochiduki S, Hasegawa T, Kitahara G, Endo TA, Toyoda T, Ohara O, Harigaya KI, Koseki H, Taniguchi M.:
    "Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells."
    J Clin Invest., 120, 2610–2618(2010).
  7. Motomura Y, Kitamura H, Hijikata A, Matsunaga Y, Matsumoto K, Inoue H, Atarashi K, Hori S, Watarai H, Zhu J, Taniguchi M, Kubo M.:
    "The transcription factor E4BP4 regulates the production of IL-10 and IL-13 in CD4+ T cells."
    Nat Immunol., 12, 450-9(2011).
  8. Watarai H, Sekine-Kondo E, Shigeura T, Motomura Y, Yasuda T, Satoh R, Yoshida H, Kubo M, Kawamoto H, Koseki H, Taniguchi M.:
    "Development and Function of Invariant Natural Killer T cells Producing TH2- and TH17-cytokines."
    PLoS Biology,10, e1001255(2012).
  9. Fujii S, Shimizu K, Okamoto Y, Kunii N, Nakayama T, Motohashi S, Taniguchi M.:
    "NKT Cells as an Ideal Anti-Tumor Immunotherapeutic."
    Front. Immunol. 4:1-7 (2013)
  10. Dashtsoodol, N, Shigeura T, Aihara M, Ozawa R, Kojo S, Harada M, Endo TA, Watanabe T, Ohara O and Taniguchi M.:
    "Alternative pathway for the development of Vα14+ NKT cells directly from CD4CD8 thymocytes that bypasses the CD4+CD8+ stage."
    Nature Immunol. 18:274–282 (2017).

Lab Members

Principal Investigator

Masaru Taniguchi
Group Director

Core Members

Nyambayar Dashtsoodol
Research Scientist
Ritsuko Ozawa
Technical Staff I
Tomokuni Shigeura
Technical Staff I
Minako Aihara
Technical Staff I

Contact information

1-7-22 Suehiro-cho, Tsurumi-ku,
Yokohama City, Kanagawa,
230-0045, Japan
Tel: +81-(0)45-503-7008
Fax: +81-(0)45-503-7015

Email: masaru.taniguchi [at] riken.jp

Related links

Recent research results

May 26, 2017: RIKEN RESEARCH
Natural born cancer killers